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Depending on intended use of a probiotic (drug vs. di-
etary supplement), regulatory requirements differ greatly. 
For dietary supplements, premarketing demonstration of 
safety and efﬁ  cacy and approval by the Food and Drug Ad-
ministration are not required; only premarket notiﬁ  cation is 
required. Saccharomyces boulardii is a probiotic regulated 
as a dietary supplement intended for use by the general 
healthy population, not as a drug to prevent, treat, or miti-
gate disease. However, since recent increases in incidence 
and severity of Clostridium difﬁ  cile infection, probiotics have 
been used to treat recurrent and/or refractory disease in 
hospitalized patients. Saccharomyces fungemia secondary 
to use of the probiotic has been described for patients who 
are critically ill, are receiving nutrition enterally, or have a 
central venous catheter. Before use of a probiotic is con-
sidered for hospitalized patients, careful assessment of risk 
versus beneﬁ  t must be made. To ensure patient safety, pro-
biotics should be properly handled during administration.
P
robiotics are deﬁ   ned by the Food and Agriculture 
Organization of the World Health Organization as 
live microorganisms that, when administered in adequate 
amounts, confer a health beneﬁ  t on the host (1). The term 
probiotic can be subcategorized to include probiotic drugs, 
probiotic foods (e.g., foods, food ingredients, and dietary 
supplements), direct-fed microbials (probiotics for animal 
use), and designer probiotics (genetically modiﬁ  ed probiot-
ics) (2). In the United States, probiotic products are mar-
keted to a generally healthy population as foods or dietary 
supplements (3).
Recent increases in the incidence and severity of 
Clostridium difﬁ  cile infection (CDI) have led some clini-
cians to consider use of probiotics as “drugs,” either alone 
or in combination with traditional antimicrobial agents for 
the prevention and treatment of CDI. Several recent re-
views have summarized results from clinical studies evalu-
ating the efﬁ  cacy of probiotics in diarrheal illness (4–12). 
Our goal is to highlight the current regulatory oversight for 
probiotics in the United States, identify potential risk situ-
ations associated with their administration, and offer sug-
gestions on practical aspects of probiotic administration to 
ensure patient safety. This review focuses on Saccharomy-
ces boulardii (Florastor; Biocodex Pharmaceutical Labora-
tories, Gentilly, France) as an example of a probiotic prod-
uct being used as a “drug” to prevent or treat recurrent CDI, 
particularly in critically ill patients.
Regulatory Oversight 
Depending on the intended use of a probiotic, whether 
as a drug or a dietary supplement, regulatory requirements 
differ. According to the Food and Drug Administration 
(FDA) deﬁ  nition, a drug is an article intended for use in the 
diagnosis, cure, mitigation, treatment, or prevention of dis-
ease (13). If a probiotic is intended for use as a drug, then 
it must undergo the regulatory process as a drug, which is 
similar to that of any new therapeutic agent. An Investi-
gational New Drug application must be submitted and au-
thorized by FDA before an investigational or biological 
product can be administered to humans. The probiotic drug 
must be proven safe and effective for its intended use be-
fore marketing (14).
If a probiotic is intended for use as a dietary supple-
ment, it is placed under the umbrella of “foods,” and as 
such is regulated by FDA’s Center for Food Safety and Ap-
plied Nutrition (15). A dietary supplement is deﬁ  ned by the 
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of 1994 as a product taken by mouth that contains a “di-
etary ingredient” intended to supplement the diet. Supple-
ments must contain >1 of the following dietary ingredients: 
a vitamin; a mineral; an herb or other botanical (excluding 
tobacco); an amino acid; a dietary substance for use by per-
sons to supplement the diet by increasing the total dietary 
intake; a concentrate, metabolite, constituent, extract; or 
combination of any of the above (16).
In contrast to drugs, dietary supplements do not need 
FDA approval before being marketed. However, manufac-
turers need to notify FDA before marketing a product. Ac-
cording to DSHEA, the manufacturer is responsible for de-
termining that the dietary supplements that it manufactures 
or distributes are safe and that any representations or claims 
made about them are substantiated by adequate evidence to 
show that they are not false or misleading; the manufactur-
ers need not provide FDA with evidence that substantiates 
the safety or purported beneﬁ  ts of their products, either be-
fore or after marketing. If a dietary supplement contains 
a new dietary ingredient that was not sold before October 
15, 1994, then the manufacturer is required to notify FDA 
and demonstrate to FDA before marketing why the ingre-
dient is reasonably expected to be safe for use in a dietary 
supplement. On June 22, 2007, FDA announced a ﬁ  nal 
rule establishing Current Good Manufacturing Practice 
requirements for dietary supplements. To ensure the iden-
tity, purity, quality, strength, and composition of dietary 
supplements, those who manufacture, package, or hold 
dietary supplements must follow these regulations (17). 
Also, since implementation of the Dietary Supplement and 
Nonprescription Drug Consumer Protection Act in 2006, 
manufacturers and distributors of dietary supplements have 
been required to record and forward to FDA any directly 
received reports of serious adverse events associated with 
use of their products. MedWatch Form 3500A (www.fda.
gov/downloads/Safety/MedWatch/HowToReport/Down-
loadForms/ucm082728.pdf) must be completed by the 
manufacturer or distributor and submitted to FDA. FDA 
encourages voluntary reporting of adverse events by health-
care professionals, consumers, or patients on MedWatch 
Form 3500 (www.fda.gov/downloads/Safety/MedWatch/
HowToReport/DownloadForms/ucm082725.pdf) (18).
Claims for Dietary Supplements
The law allows that in addition to nutrient content 
claims, manufacturers of dietary supplements may make 
structure/function or health claims for their products. For 
a structure/function claim, FDA requires that manufactur-
ers’ substantiation is accepted by experts in the ﬁ  eld and 
that the claim is truthful and not misleading. The data sub-
stantiating structure/function claims need not be publicly 
available and need not be disclosed. In general, the level of 
substantiation and the quality of evidence needed to make a 
structure/function claim are less than that needed to make a 
health claim. When a structure/function claim is made, the 
manufacturer must state in a disclaimer that FDA has not 
evaluated the claim and that the product is not intended to 
“diagnose, treat, cure, or prevent any disease”; such a claim 
can legally be made only with regard to a drug (19,20).
According to FDA, “health claims describe a relation-
ship between a food, food component, or dietary supplement 
ingredient, and reducing risk of a disease or health-related 
condition.” In contrast, a structure/function claim describes 
the process by which the dietary supplement, conventional 
food, or drug maintains normal functioning of the body and 
does not need FDA approval before marketing. The data 
substantiation requirements for the claims described above 
vary greatly. Before a health claim is authorized, a petition 
containing the scientiﬁ  c evidence supporting the claim is re-
viewed by FDA. The systematic review process for a health 
claim involves deﬁ  ning the relationship between probiotic 
and disease and identifying relevant studies supporting the 
claim. Clinical studies are then rated on the basis of quality 
and strength of evidence. Only data obtained from stud-
ies conducted in healthy populations are evaluated because 
health claims are usually directed at the general population 
or certain subgroups (e.g. elderly patients). The data sup-
porting a health claim must be published and therefore ap-
ply to any product meeting the criteria for the claim (21).
Global Standards for Evaluation of Probiotics
In 2001, in an attempt to standardize the requirements 
needed to make health claims regarding probiotic agents, 
the Joint Food and Agriculture Organization of the United 
Nations/World Health Organization Expert Consultation 
on Evaluation of Health and Nutritional Properties of Pro-
biotics developed guidelines for evaluating probiotics in 
food that could lead to the substantiation of health claims 
(1). The proposed guidelines recommend 1) identiﬁ  cation 
of the genus and species of the probiotic strain by using a 
combination of phenotypic and genotypic tests as clinical 
evidence suggesting that the health beneﬁ  ts of probiotics 
may be strain speciﬁ  c, 2) in vitro testing to delineate the 
mechanism of the probiotic effect, and 3) substantiation 
of the clinical health beneﬁ  t of probiotic agents with hu-
man trials. Additionally, safety assessment of the probiotic 
strain should at a minimum determine 1) patterns of anti-
microbial drug resistance, 2) metabolic activities, 3) side 
effects noted in humans during clinical trials and after mar-
keting, 4) toxin production and hemolytic potential if the 
probiotic strain is known to possess those properties, and 
5) lack of infectivity in animal studies.
The Consultation recommends that speciﬁ  c  health 
claims on labeling material on probiotic food items be al-
lowed when sufﬁ  cient scientiﬁ  c evidence is available and 
that the product manufacturer take responsibility for ensur-
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ing that an independent third party reviews and evaluates 
the scientiﬁ  c evidence. Since development of these guide-
lines, only a few manufacturers have conducted small, ran-
domized, controlled studies in humans to prove efﬁ  cacy 
and safety of their products. Until more stringent regula-
tions are in place, when assessing therapeutic potential 
for a probiotic product, clinicians must weigh the avail-
able evidence as outlined above. In addition, the manufac-
turer should take on the responsibility (albeit not required 
by law) of providing guidance to consumers or clinicians 
about the type and extent of safety assessments that have 
been conducted on its products.
S. boulardii as Probiotic
Since the 1950s, S. boulardii has been used interna-
tionally and extensively as a probiotic (22). S. boulardii is a 
live yeast that has been lyophilized and is available in 250-
mg capsules for adults. The probiotic may be prescribed 
as 1–2 capsules to be taken 1–2×/day (23). In the United 
States, S. boulardii is marketed as a dietary supplement. 
The product package displays the following structure/func-
tion claims: 1) maintains the balance of the intestinal ﬂ  ora, 
2) keeps intestines functioning well, and 3) promotes intes-
tinal health.
Use of S. boulardii in Patients with CDI
Studies of S. boulardii in populations other than the 
healthy general public have demonstrated its efﬁ  cacy for 
reducing recurrence of CDI when used in combination with 
standard therapy. A multicenter, double-blind, placebo-
controlled trial investigated the effects of S. boulardii (1 
g/d) for 4 weeks in combination with vancomycin (high 
dose 2 g/d or low dose 500 mg/d) or metronidazole (1 g/
day) to patients with either initial or recurrent CDI (24). 
Recurrence rates were 16.7% for patients receiving S. bou-
lardii with high-dose vancomycin compared with 50% for 
patients receiving high-dose vancomycin and placebo (p = 
0.04). Rates for recurrent CDI did not differ when S. bou-
lardii was combined with either low-dose vancomycin or 
metronidazole. According to the 2010 guidelines for man-
agement of CDI in adults, published jointly by the Society 
of Healthcare Epidemiology of America and the Infectious 
Diseases Society of America, no compelling evidence ex-
ists to support routine use of probiotics for prevention or 
treatment of CDI (25).
Infectious Complications after Receipt of 
S. boulardii
Safety of dietary supplements is conducted postmar-
keting. Therefore, much of the safety data on use of S. bou-
lardii as a probiotic “drug” are derived from case reports. 
Saccharomyces fungemia is the most severe complication 
secondary to administration of the probiotic. S. cerevisiae 
and S. boulardii have been referred to in the literature inter-
changeably and have recently been shown by genetic ﬁ  n-
gerprinting and gene sequencing to be similar on a genetic 
level and to possibly share metabolic properties (26).
The most comprehensive literature review on inci-
dence of invasive Saccharomyces infections was conducted 
by Enache-Angoulvant et al. (27). They identiﬁ  ed 91 docu-
mented cases of invasive Saccharomyces infection in the 
literature (54 cases of S. cerevisiae invasive infections vs. 
37 cases of S. boulardii fungemia). In particular, patients 
infected with S. boulardii were more likely than patients 
infected with S. cerevisiae to have digestive tract disease 
(58% vs. 6%; p<0.01), to have intravenous catheters (83% 
vs. 29%; p<0.0001), and to be hospitalized in an intensive 
care unit (32% vs. 0.05%, p<0.01). The use of biothera-
peutic agents containing S. boulardii was associated with 
40% of all invasive cases. A previously conducted litera-
ture review by Muñoz et al. identiﬁ  ed 60 cases of fungemia 
caused by S. cerevisiae (28). Of note, 48% of patients with 
fungemia had received a S. boulardii probiotic preparation, 
and another 8% were near patients who had received these 
agents. The latter ﬁ  nding suggests that S. boulardii admin-
istration presents an environmental risk for patients who 
are not receiving the agents.
When Hennequin et al. investigated air and surface 
contamination related to the opening of a 500-mg packet 
of freeze-dried S. boulardii, they found that the simple act 
of opening a packet of S. boulardii produced substantial air 
contamination (29). Organisms persisted on the arm of the 
simulated patient 30 minutes after the product was opened 
and as long as 2 hours on the surrounding table surface. The 
hands of the technician who had opened the packet were 
noted to be highly and persistently contaminated despite 
vigorous handwashing.
Several factors constitute excessive and undue risk for 
development of Saccharomyces fungemia during probi-
otic administration. These factors are the patient’s immu-
nocompromised state during critical illness, the potential 
for live yeast spore contamination of healthcare workers’ 
hands during preparation of the probiotic capsule for ad-
ministration, and introduction of live yeast from contami-
nated hands to catheter sites (and patient’s bloodstream).
Ensuring Patient Safety 
Hospitalized patients for whom clinicians may con-
sider use of a probiotic to manage severe and/or recurrent 
CDI often have many of the above risk factors for develop-
ment of fungemia, making administration of S. boulardii 
less than desirable and its routine use unsafe. Guideline 
experts speciﬁ  cally recommend that administration of S. 
boulardii be avoided for persons who are immunocompro-
mised, are critically ill, or have a central venous catheter 
(25). The Florastor package insert even recommends that 
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patients with a central venous catheter consult a healthcare 
professional before starting therapy and further mentions 
that “very rare cases of fungemia have been observed in 
patients with a central venous catheter.”
Institutional guidelines are needed to address the po-
tential safety issues related to S. boulardii use. After the 
decision is made to use probiotics on the basis of careful 
risk assessment, we suggest that the following measures be 
taken: 1) healthcare providers should wear gloves during 
the handling of probiotic agents for administration, then 
promptly discard the gloves and properly wash their hands 
with soap and water, 2) drug capsules should not be opened 
near patients with central venous catheters because aero-
solized spores could cross-contaminate sterile sites (i.e., 
enter blood through catheter site) of patients receiving the 
probiotic as well as other patients nearby, 3) enteral admin-
istration of S. boulardii should be avoided because of the 
risk for environmental contamination and cross-contamina-
tion when the seal of the capsule is opened.
Probiotic products contain different genera, differ-
ent species, or even different strains of the same species. 
Although the safety concerns noted here for S. boulardii 
may not be extrapolated to other probiotics such as lactoba-
cilli, biﬁ  dobacteria, and others, use of any probiotic dietary 
supplement as a drug in diseased or immunocompromised 
populations requires speciﬁ  c evaluation of safety in that 
population.
Conclusions
The recent increase in incidence and severity of disease 
caused by hypervirulent strains of C. difﬁ  cile has prompted 
some clinicians to prescribe probiotics as drugs in combi-
nation with standard antimicrobial drug therapy for these 
patients. However, clinicians need to be aware that, unlike 
drugs, these probiotic dietary supplements are not required 
by FDA to undergo rigorous premarketing evaluations for 
efﬁ  cacy or safety.
Albeit rare, serious complications (i.e., fungemia) in 
other than healthy populations receiving probiotics have 
been reported in the literature. Speciﬁ  cally, most compli-
cations related to the administration of S. boulardii have 
occurred in immunocompromised or critically ill patients 
or in those who had central venous catheters serving as 
a portal of entry of organisms from healthcare workers’ 
contaminated hands to patients’ bloodstream during ad-
ministration. Careful risk assessment for patients and 
proper handling of the probiotic during administration 
need to be conducted before using probiotics as drugs in 
institutional settings. Vigilant reporting of adverse events 
resulting from probiotic use is necessary to establish the 
safety proﬁ  le of these agents when they are used in other 
than healthy populations.
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